Skip to content
Altius – Lifestyle
Author:
Herantis Pharma plc
Herantis Pharma releases 1H 2026 report today
August 20, 2026
Herantis appoints experienced drug development expert Dr Juha Savola as Chief Medical Officer
June 25, 2026
Herantis reports positive FDA feedback and finalizes Phase 2a study design for HER-096
June 2, 2026
Herantis Pharma partners with Indivi to enable detection of early treatment effects in upcoming HER-096 Phase 2 trial in Parkinson’s disease
May 19, 2026
Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease
May 16, 2026
Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn’s disease
May 16, 2026
ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis
March 30, 2026
FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
March 18, 2026
Herantis Pharma to present HER-096 Phase 1b data at International Conference on Alzheimer’s & Parkinson’s Diseases
March 16, 2026
Herantis Pharma releases 2H and FY 2025 report today
March 5, 2026